09:21:07 EDT Tue 22 Sep 2020
Enter Symbol
or Name

Login ID:

Cannabis Summary for Feb. 25, 2020

2020-02-25 19:44 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

As the broader market continued to fall on coronavirus fears, the S&P/TSX Cannabis Index dropped 6.66 points to 169.26 Tuesday, while the Canadian Securities Exchange Composite Index dropped 12.7 points to 361.89. Tyler Robson's Valens Groworks Corp. (VLNS) fell 22 cents to $3.73 on 1.73 million shares after releasing its fiscal fourth quarter results (for the period ending Nov. 30, 2019). While shareholders were in a selling mood, the drop in the stock's price may have had more to do with the general market decline than anything specific to Valens.

The extractor's fiscal Q4 revenue increased to $30.6-million, up from $16.5-million in Q3. In general, extractors such as Valens and Medipharm Labs Corp. (LABS: $2.60) (extractors process marijuana into extract products such as edibles or oils) have delivered much stronger revenue growth than their marijuana-growing peers. Still, the $30.6-million in revenue beat Valens's guidance range ($27-million to $30-million).

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2020 Canjex Publishing Ltd. All rights reserved.

Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.